ABSTRACT Trimethylamine-N-oxide (TMAO) is an end-product of gut microbiome
metabolism linked to cardiovascular disease (CVD). However, precise cardiovascular …

There is increasing appreciation that changes in microbiome composition and function can
promote long-term susceptibility for cardiometabolic risk. Gut microbe-derived metabolites …

Morbidity and mortality of cardiovascular diseases (CVDs) are exceedingly high worldwide.
Researchers have found that the occurrence and development of CVDs are closely related …

Background Patients at increased risk for coronary artery disease and adverse prognosis
during heart failure exhibit increased levels of circulating trimethylamine N‐oxide (TMAO), a …

Aim: Trimethylamine N-oxide (TMAO) is a gut microbiota-derived metabolite synthesized in
host organisms from specific food constituents, such as choline, carnitine and betaine …

An increasing amount of evidence reveals that the gut microbiota is involved in the
pathogenesis and progression of various cardiovascular diseases. In patients with heart …

Meanwhile, the contributions of structurally specific gut microbiota-generated metabolites to
cardiovascular and metabolic health have emerged as a multifaceted area of research with …

Excessive consumption of diets high in sugars and saturated fat, frequently known as
western diet (WD), may lead to obesity and metabolic syndrome. Recent evidence shows …

Although traditional cardiovascular risk factors are well established and understood,
mortality and morbidity in patients with cardiovascular disease (CVD) remains high …

Background Accumulation of intestinal microbial-dependent dietary phosphatidylcholine
metabolite, trimethylamine N-oxide (TMAO), has been associated with coronary artery …